Wire · opportunities
Lunit looks to bring pathology AI into drug development through US lab deal
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 12 October 2026 · Fusion42 review
Korean AI medical company Lunit has partnered with US lab Discovery Life Sciences to integrate its pathology AI software into drug development workflows, targeting pharmaceutical biomarker research. The deal aims to embed Lunit's SCOPE platform into tissue analysis processes across numerous clinical trials to enhance data consistency in biomarker evaluation.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You can now embed pathology AI into pharmaceutical research at scale through lab partnerships like Lunit's deal with Discovery Life Sciences. This opens a direct route to biopharma clients that rely on biomarker data for drug trials, so speed your outreach to lab service providers integrating AI tech.
◆ Coverage
1 source · 12 Oct 2026
◆ Related on Wire
◆ Topics